Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®

Posted On: 2020-07-12 23:28:57


Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu® to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study.

Further, Glenmark has announced a price reduction of 27% for FabiFlu®. The new MRP is INR 75 per tab from the earlier INR 103 per tab. The price reduction has been made possible through benefits gained from higher yields and better scale, as both the API and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country.

Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu® through its own in-house R&D team within the country, ensuring self-reliance with regard to longterm production and manufacturing. The API is manufactured at the Gujarat production facility which is USFDA & MHRA-UK approved. The formulation product is manufactured at the facility in Himachal Pradesh, which is also USFDA and MHRA-UK approved.

Commenting on these developments, Mr. Alok Malik, Senior Vice President & Head - India business, Glenmark Pharmaceuticals Ltd., said, "We expect this post marketing surveillance study to shed more light on the drug's clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu®. Our priority from the start of this pandemic has been to offer patients in India an effective treatment for COVID-19, while also ensuring accessibility to the masses. Our internal research shows us that we launched FabiFlu® in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country."

Despite investing significantly in R&D, clinical trials and the manufacturing of FabiFlu®(API and formulations), Glenmark has managed to keep the pricing of FabiFlu® lower as compared to its price in other countries. FabiFlu® in India was originally launched at INR 103/tab, while, its price as INR is higher in the remaining countries. (INR 600/tab in Russia, INR 378/tab in Japan, INR 350/tab in Bangladesh and INR 215/tab in China). *Based on trade data available for 200mg /tab from the respective countries and currency rates in respective countries equivalent to INR recorded.

On June 20th, Glenmark announced that it received manufacturing and marketing approval from India's drug regulator for FabiFlu®, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19. The manufacturing and marketing approval was granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval's restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Most patients exhibiting mild to moderate symptoms can benefit from FabiFlu® use. Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu®) in mild to moderate COVID-19 patients in India. The trial results will be available shortly.

Glenmark is also conducting another Phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India. The combination study which is called the FAITH trial is looking to enroll 158 hospitalized patients of moderate COVID-19 in India. Early treatment with combination therapy will be evaluated for safety and efficacy as it is emerging as an effective approach in shortening duration of virus shedding, facilitating early clinical cure and discharge of patients.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.426.7 as compared to the previous close of Rs. 431.75. The total number of shares traded during the day was 251044 in over 8705 trades.

The stock hit an intraday high of Rs. 439.4 and intraday low of 425.25. The net turnover during the day was Rs. 108530857.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Sinclairs Hotels Ltd Q1 PAT at Rs. 0.48 crore

National Fittings Ltd Q1 loss at Rs. 0.68 crore

NESCO Ltd posts consolidated PAT of Rs. 51.32 crore in Q1FY21

MRF Ltd Q1FY21 consolidated net profit plunges to Rs. 13.46 crore

NIRLON Ltd reports Rs. 32.47 crore PAT in Q1

Valiant Communications Ltd Q1 consolidated net loss at Rs. 0.44 crore

Punjab Alkalies and Chemicals Ltd Q1 loss widens to Rs. 3.32 crore

The Ramco Cements Ltd Q1FY21 consolidated PAT at Rs. 117.25 crore

XPRO India Ltd Q1 consolidated loss at Rs. 12.70 crore

Infosys to accelerate Digital Skills and Innovation across Australia and New Zealand via its GovHack 2020 partnership

Wonderla Holidays Ltd. launches 2nd Wonder Kitchen Outlet at Rajarajeshwari Nagar, Bangalore

Parag Milk Food Ltd. introduces a new product to its premium category by launching Pride of Cows Curd

Mindteck Reports Financial Results for Q1 2020-21

Steel Strips Wheels Ltd promoter group release 44132 shares from pledge

Shriram Transport Finance Company Ltd announces Q1FY21 results

The Tata Power Company Ltd allots 49,05,66,037 Equity Shares to Tata Sons

Hero MotoCorp announces Q1FY21 results

Trent Ltd announces Q1 FY21 results

Minda Corporation Ltd Q1 consolidated loss at Rs. 35.40 crore

TATA Steel Ltd Q1 consolidated loss at Rs. 4648.13 crore

TIMKEN India Ltd Q1 PAT slumps to Rs. 3.15 crore

Mindteck India Ltd Q1FY21 consolidated net profit at Rs. 1.67 crore

TNPL reports earnings for Q1FY21

Balkrishna Industries Ltd board declares interim dividend of Rs. 3 for FY21

CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

JSPL becomes first company to supply Head Hardened rails to Metro Rail projects in India

Paisalo Digital Ltd reports Rs. 15.06 crore consolidated PAT in Q1FY21

Hindustan Tin Works Ltd Q1 PAT at Rs. 0.79 crore

Shivalik Rasayan Ltd Q1 consolidated PAT lower at Rs. 2.50 crore

Rossell India Ltd Q1FY21 PAT soars to Rs. 9.12 crore

Shriram Transport Finance Company Ltd Q1FY21 consolidated net profit climbs QoQ to Rs. 319.25 crore

Excel Industries Ltd Q1FY21 consolidated PAT declines to Rs. 8.21 crore

Amines & Plasticizers Ltd Q1 consolidated PAT rises to Rs. 7.61 crore

Ishita Drugs & Industries Ltd posts PAT of Rs. 0.09 crore in Q1

PG Electroplast Ltd Q1FY21 loss widens to Rs. 8.48 crore

Orient Bell Ltd Q1 consolidated loss at Rs. 11.42 crore

Hercules Hoists Q1FY21 profit plunges to Rs. 0.24 crore

I G Petrochemicals posts consolidated PAT of Rs. 2.22 crore in Q1FY21

Endurance Technologies Ltd Q1FY21 consolidated loss at Rs. 24.90 crore

Balkrishna Industries Ltd Q1 consolidated PAT slides to Rs. 131.56 crore

BPCL Q1FY21 consolidated net profit at Rs. 2035.39 crore

AGC Networks completes the acquisition of Pyrios

Eicher Motors Limited announces financial results for the quarter ended June 30, 2020

TCS a Leader and Star Performer in Healthcare Provider Digital Services: Everest Group

GAIL reports Turnover of Rs. 12,060 crore, PAT of Rs. 256 crore in Ql FY21

Ahluwalia Contracts secures new order of Rs. 290 crore

Wipro Limited recognized as the winner of Data Estate Modernization 2020 Microsoft Partner of the Year

SKM Egg Products Export India Ltd board recommends final dividend of Rs. 0.50 for FY20

L&T Construction bags significant contracts from prestigious clients

Shoppers Stop Reported Revenue of Rs.60.7 Crs and EBITDA Loss of Rs. 132.8 Crs in Q1FY21







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019